U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07188012) titled 'Safety and Dystrophin Expression of SPOT-mRNA03 in Duchenne Muscular Dystrophy (DMD) Patients' on Aug. 22.
Brief Summary: The primary objective of this study is to evaluate the safety and and tolerability of SPOT-mRNA03 administered by intravenous (IV) infusion to DMD patients. In addition, this study will preliminarily investigate the concentration changes in dystrophin mRNA concentration, dystrophin protein expression and engraftment, as well as cytokine profiles and immunogenicity.
Study Start Date: Aug. 06
Study Type: INTERVENTIONAL
Condition:
Duchenne Muscular Dystrophy (DMD)
Intervention:
GENETIC: mRNA
mRNA therapy del...